14 Mar 2019 07:00
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
4D pharma plc
(the "Company" or "4D")
PDMR Dealings
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that Duncan Peyton and Alex Stevenson (the "Directors") have purchased ordinary shares in the Company as listed below. Following this transaction, the Directors have a resulting interest in the ordinary shares of the Company as listed below.
Name | Shares in 4D pharma plc before purchase | % of total shares in issue | Shares in 4D pharma plc after purchase | % of total shares in issue | |
Duncan Peyton (CEO) | 6,337,215 | 9.68% | 6,343,985 | 9.69% | |
Alex Stevenson (CSO) | 6,337,242 | 9.68% | 6,362,138 | 9.71% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities / person closely associated |
| ||||||||
a) | Name | Duncan Peyton |
| |||||||
2 | Reason for the notification |
| ||||||||
a) | Position/status | PDMR |
| |||||||
b)
| Initial notification /Amendment | Initial notification |
| |||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||||||
a) | Name | 4D Pharma plc |
| |||||||
b) | LEI | 213800O49VYSXWE2ZD52 |
| |||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| ||||||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.0025
ISIN: GB00BJL5BR07 |
| |||||||
b) | Nature of the transaction | Purchase of Ordinary Shares |
| |||||||
c) | Price(s) and volume(s) |
|
| |||||||
d) | Aggregated information - Aggregated volume - Price |
N/A
|
| |||||||
e) | Date of the transaction | 13th March 2019 |
| |||||||
f) | Place of the transaction | London Stock Exchange, AIM |
| |||||||
|
|
| ||||||||
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||||
a) | Name | Alex Stevenson | ||||||||
2 | Reason for the notification | |||||||||
a) | Position/status | PDMR | ||||||||
b)
| Initial notification /Amendment | Initial notification | ||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | 4D Pharma plc | ||||||||
b) | LEI | 213800O49VYSXWE2ZD52 | ||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.0025
ISIN: GB00BJL5BR07 | ||||||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information - Aggregated volume - Price |
N/A
| ||||||||
e) | Date of the transaction | 13th March 2019 | ||||||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||||||
|
| |||||||||
For further information please contact:
4D | |
Duncan Peyton, Chief Executive Officer Fay Weston, Head of Investor Relations
| + 44 (0)113 895 0130 + 44 (0)7990 381713 |
Zeus Capital Limited - Nomad and Joint Broker | +44 (0)161 831 1512 |
Dan Bate / Jordan Warburton
| |
Bryan Garnier & Co. Limited - Joint Broker | +44 (0)20 7332 2500 |
Dominic Wilson Phil Walker |
DDDD.L (DDDD)